coli O157:H7 and Shigella dysenteriae
genomic DNA, respectively, were prepared and all the steps were carried out as described previously.
814 99 Methylobacterium persicinum (3) N/I (4) 98 Shigella dysenteriae
GlycoVaxyn's shigella vaccine consists of a polysaccharide of Shigella dysenteriae
O1 conjugated to a protein carrier.
RESUMEN: El objetivo del presente trabajo ha sido evaluar el dano celular agudo generado por el producto de excrecion de Shigella dysenteriae
sobre el tejido muscular del miembro inferior de embrion de pollo, asi como sobre los mioblastos obtenidos a partir del cultivo de explantes de tejido muscular desarrollado en gota pendiente.
Our vaccine shows a higher percentage of seroconversion compared to previous Shigella dysenteriae
vaccines tested in clinical trials.
Antimicrobial activity was tested against Staphylococcus aureus, Eschericha coli, Pseudomouns aeruginosa, Salmonella typhi, Shigella boydii, Shigella flexneri and Shigella dysenteriae
were obtained from International Centre for Diarrheal Disease Research, Bangladesh (ICDDR, B) (29).
23 February 2010 - Swiss conjugate vaccines maker GlycoVaxyn said today it has started a Phase I study of its vaccine candidate (GVXN SD133) against Shigella dysenteriae
, a cause of serious intestinal infections.
The extracts will be individually tested against a panel of microorganisms, including Aspergillus niger ATCC 16404, Candida albicans ATCC 10231, Escherichia coli ATCC 10536, Klebsiella pneumoniae ATCC 10031, Proteus vulgaris PTCC 1182, Pseudomonas aeruginosa ATCC 27853, Salmonella paratyphi-A serotype ATCC 5702, Shigella dysenteriae
PTCC 1188, Staphylococcus aureus ATCC 29737, Staphylococcus epidermidis ATCC 12228.
, Shigella flexneri, Shigella boydii and Shigella sonnei constitute the four species of the genus.
In parallel to this innovative approach, GlycoVaxyn, which started Phase I clinical trials with a bioconjugate vaccine against Shigella dysenteriae
early this year, is expecting to start a clinical trial with its first generation S.
Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae
Acetone soluble fraction demonstrated activity against Shigella dysenteriae